These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 9201802)
1. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Kapur S; Zipursky R; Roy P; Jones C; Remington G; Reed K; Houle S Psychopharmacology (Berl); 1997 May; 131(2):148-52. PubMed ID: 9201802 [TBL] [Abstract][Full Text] [Related]
2. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Fitzgerald PB; Kapur S; Remington G; Roy P; Zipursky RB Psychopharmacology (Berl); 2000 Mar; 149(1):1-5. PubMed ID: 10789875 [TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Nyberg S; Nordström AL; Halldin C; Farde L Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():81-5. PubMed ID: 8866769 [TBL] [Abstract][Full Text] [Related]
4. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Kapur S; Remington G; Jones C; Wilson A; DaSilva J; Houle S; Zipursky R Am J Psychiatry; 1996 Jul; 153(7):948-50. PubMed ID: 8659621 [TBL] [Abstract][Full Text] [Related]
5. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348 [TBL] [Abstract][Full Text] [Related]
6. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598 [TBL] [Abstract][Full Text] [Related]
7. A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors. Ishiwata K; Oda K; Sakata M; Kimura Y; Kawamura K; Oda K; Sasaki T; Naganawa M; Chihara K; Okubo Y; Ishii K Ann Nucl Med; 2006 Oct; 20(8):569-73. PubMed ID: 17134027 [TBL] [Abstract][Full Text] [Related]
9. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964 [TBL] [Abstract][Full Text] [Related]
10. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Olsen CK; Brennum LT; Kreilgaard M Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493 [TBL] [Abstract][Full Text] [Related]
11. The D2 receptor occupancy profile of loxapine determined using PET. Kapur S; Zipursky RB; Jones C; Remington GJ; Wilson AA; DaSilva J; Houle S Neuropsychopharmacology; 1996 Dec; 15(6):562-6. PubMed ID: 8946430 [TBL] [Abstract][Full Text] [Related]
12. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. Nyberg S; Farde L; Halldin C Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776 [TBL] [Abstract][Full Text] [Related]
13. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Nordström AL; Farde L; Halldin C Psychopharmacology (Berl); 1992; 106(4):433-8. PubMed ID: 1533719 [TBL] [Abstract][Full Text] [Related]
14. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577 [TBL] [Abstract][Full Text] [Related]
15. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858 [TBL] [Abstract][Full Text] [Related]
16. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Ginovart N; Wilson AA; Hussey D; Houle S; Kapur S Neuropsychopharmacology; 2009 Feb; 34(3):662-71. PubMed ID: 18688210 [TBL] [Abstract][Full Text] [Related]
17. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818 [TBL] [Abstract][Full Text] [Related]
18. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646 [TBL] [Abstract][Full Text] [Related]
19. Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study. Lim HS; Kim SJ; Noh YH; Lee BC; Jin SJ; Park HS; Kim S; Jang IJ; Kim SE Pharm Res; 2013 Mar; 30(3):683-93. PubMed ID: 23138261 [TBL] [Abstract][Full Text] [Related]
20. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride. Bench CJ; Lammertsma AA; Dolan RJ; Grasby PM; Warrington SJ; Gunn K; Cuddigan M; Turton DJ; Osman S; Frackowiak RS Psychopharmacology (Berl); 1993; 112(2-3):308-14. PubMed ID: 7871035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]